RBC Capital raised the firm’s price target on Boston Scientific to $82 from $78 and keeps an Outperform rating on the shares. Given the company’s Q1 momentum on seales and earnings, along with its new product ramp, the management’s updated FY24 guidance is likely “conservative” despite easier comps, the analyst tells investors in a research note. RBC adds that the stock is its top pick in the Sector based on its “industry-leading growth profile”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific sees FY24 adjusted EPS $2.29-$2.34, consensus $2.25
- Boston Scientific sees Q2 adjusted EPS 57c-59c, consensus 56c
- Boston Scientific reports Q1 adjusted EPS 56c, consensus 51c
- Boston Scientific Announces Results for First Quarter 2024
- Notable companies reporting before tomorrow’s open